A novel intronic circular RNA circFGFR1int2 up-regulates FGFR1 by recruiting transcriptional activators P65/FUS and suppressing miR-4687-5p to promote prostate cancer progression

Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 21; no. 1; pp. 1 - 840
Main Authors Wang, Ruyue, Zhong, Jinjing, Pan, Xiuyi, Su, Zhengzheng, Xu, Yunyi, Zhang, Mengni, Chen, Xueqin, Chen, Ni, Yu, Ting, Zhou, Qiao
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 22.11.2023
BioMed Central
BMC
Subjects
1-Phosphatidylinositol 3-kinase
AKT protein
Analysis
Antibodies
Binding sites
Care and treatment
Cell migration
Chromatin
Chromosomes
circRNA
Circular RNA
Development and progression
Epigenetics
Extracellular signal-regulated kinase
FGFR1
Fibroblast growth factor receptor 1
Fibroblast growth factors
Fibroblasts
FUS
Gene amplification
Gene mutations
Gene rearrangement
Genetic aspects
Health aspects
Hybridization
Kinases
Medical prognosis
MicroRNA
miRNA
Mutation
NF-κB protein
P65
Point mutation
Post-transcription
Prostate cancer
Proteins
Signal transduction
Sperm
Survival analysis
Therapeutic targets
Transcription factors
Transcription regulation
Tumors
China
Online AccessGet full text

Cover

Abstract Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1 int2 , derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1 int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1 int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1 int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) ( RR  = 3.277, 95% confidence interval: 1.192–9.009; P  = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. Graphic Abstract
AbstractList Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192–9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target.Graphic Abstract
Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLC[gamma], and NF-?B. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1.sup.int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1.sup.int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1.sup.int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1.sup.int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192-9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. Graphic Keywords: circRNA, FUS, P65, miRNA, FGFR1, Transcription regulation, Prostate cancer
Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192–9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. Graphic Abstract
Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1 int2 , derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1 int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1 int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1 int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) ( RR  = 3.277, 95% confidence interval: 1.192–9.009; P  = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. Graphic Abstract
Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLC[gamma], and NF-?B. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1.sup.int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1.sup.int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1.sup.int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1.sup.int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192-9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target.
Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192-9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target.
ArticleNumber 840
Audience Academic
Author Su, Zhengzheng
Zhang, Mengni
Zhou, Qiao
Zhong, Jinjing
Xu, Yunyi
Wang, Ruyue
Pan, Xiuyi
Chen, Xueqin
Chen, Ni
Yu, Ting
Author_xml – sequence: 1
  fullname: Wang, Ruyue
– sequence: 2
  fullname: Zhong, Jinjing
– sequence: 3
  fullname: Pan, Xiuyi
– sequence: 4
  fullname: Su, Zhengzheng
– sequence: 5
  fullname: Xu, Yunyi
– sequence: 6
  fullname: Zhang, Mengni
– sequence: 7
  fullname: Chen, Xueqin
– sequence: 8
  fullname: Chen, Ni
– sequence: 9
  fullname: Yu, Ting
– sequence: 10
  fullname: Zhou, Qiao
BookMark eNptUk1rGzEQXUoKTdL-gZ4EvfSyib61ezShTgMhLW5zFtqxZGTW0lbSBvy38gsr26FfFB1GM3rvjWZ4F81ZiME2zXuCrwjp5HUmtJeqxZS1mCvStftXzTnhqm9Fp-TZH_c3zUXOW4wpF7w_b54XKMQnOyIfSorBAwKfYB5NQquHxTFZ3i5XpD5TNE9tspv6WGxGxzIa9ihZSLMvPmxQSSZkSH4qPgYzIgPFP5kSU0ZfpbhePn5DJqxRnqcp2ZwPlJ1ftVx2qhUTKhFNKe5isYeYS-2DwASw6ZBvjpQY3javnRmzffcSL5vH5afvN5_b-y-3dzeL-xY4EaV1HKQE64QUdVZgzDpppeKOMCYxHthQl-AGAo4YLjl1ivZglKtk53An2GVzd9JdR7PVU_I7k_Y6Gq-PhZg22qTiYbSaDa5zDPCadpLLwfYdOOOoXPcGDwKrqvXxpFXn-DHbXPTOZ7DjaIKNc9a062nPJZGyQj_8A93GOdVtVlSPKWH1a_g3amNqfx9crLuHg6heKMU6JQShFXX1H1Q9a7vzUC3kfK3_RaAnAtT952Tdr7kJ1gen6ZPTdHWaPjpN79lPjKnIGg
CitedBy_id crossref_primary_10_1016_j_ncrna_2024_03_012
Cites_doi 10.1016/j.gene.2009.03.004
10.1002/wrna.1338
10.1172/jci.insight.120594
10.1038/s41467-021-25082-9
10.1038/s41467-020-19381-w
10.1016/j.phrs.2019.104567
10.1101/gad.277137.115
10.1111/cas.15240
10.1038/s41467-023-40212-1
10.1186/s40478-020-00898-6
10.1210/en.2007-0114
10.1016/j.sbi.2019.07.012
10.1101/gad.204602.112
10.1091/mbc.e10-04-0290
10.1038/ng.2434
10.1016/j.tcb.2014.11.003
10.1038/s41556-021-00639-4
10.1074/jbc.M108411200
10.1038/nsmb.2959
10.1002/tox.23640
10.1016/j.canlet.2018.02.015
10.1016/j.jmb.2016.02.019
10.1038/s41419-019-2028-9
10.1016/j.it.2022.07.004
10.1152/physrev.00005.2020
10.1038/nrc2780
10.1016/j.canlet.2021.10.011
10.1158/1541-7786.MCR-17-0185
10.1111/cas.15694
10.1159/000335180
10.1002/med.21288
10.1016/j.gene.2007.06.010
10.1016/j.pharmthera.2020.107715
10.1007/s11060-021-03890-9
10.1016/j.celrep.2014.12.019
10.1038/s41418-018-0220-6
10.1186/s40478-020-01027-z
10.1016/j.bbcan.2021.188595
10.1371/journal.pmed.1002847
10.1038/ncomms14741
10.1038/s41586-021-03922-4
10.1016/j.yjmcc.2007.12.008
10.1158/0008-5472.CAN-22-3997
10.1111/jop.12773
10.1186/s12943-019-1111-2
10.1016/j.cell.2015.02.014
10.1128/mBio.01017-21
10.1126/scitranslmed.3009332
10.7554/eLife.40033
10.1074/jbc.M113.457648
10.1016/j.euo.2021.10.001
10.1016/S0140-6736(21)00950-8
10.1186/s13046-018-0813-4
10.1074/jbc.M011176200
10.1016/j.ejca.2021.04.005
10.1186/s13148-021-01212-4
10.1007/s00109-013-1077-2
10.3389/fmed.2022.861960
10.1158/0008-5472.CAN-13-1093
10.1016/j.celrep.2020.107641
10.1074/jbc.M113.493874
10.1017/S0022149X2000098X
10.1016/j.omtn.2019.01.003
10.1016/j.canlet.2022.01.016
10.1016/j.ando.2019.10.002
10.1038/s41467-019-12049-0
10.1016/j.molcel.2016.11.034
10.1158/2159-8290.CD-23-0004
10.1097/MPA.0000000000002119
10.1038/nature11993
10.1093/nar/gkaa035
10.1016/j.molcel.2021.07.042
10.1074/jbc.M410744200
10.1038/nrdp.2017.44
10.1038/onc.2011.140
10.1016/j.cell.2019.01.025
10.1038/s41571-021-00585-y
10.1016/j.ccell.2023.05.002
10.1016/j.neulet.2019.03.048
10.1186/s13059-014-0409-z
10.1158/1078-0432.CCR-14-3212
10.1186/s13073-018-0545-2
10.18632/oncotarget.2740
10.1186/s13046-020-01552-8
10.1016/j.yexcr.2009.08.008
10.1038/nrurol.2014.270
ContentType Journal Article
Copyright COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOA
DOI 10.1186/s12967-023-04718-y
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
Immunology Abstracts
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database


CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 840
ExternalDocumentID oai_doaj_org_article_3bf8f3c0d28646be98cfaf26d9a0b507
A773875512
10_1186_s12967_023_04718_y
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
-A0
0R~
29L
2WC
3V.
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACRMQ
ADBBV
ADINQ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
ABVAZ
AFGXO
AFNRJ
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c415t-f4c66cef565245c33ef6e674f133600b3b002fb1cf1a4642f729ca7f415ff0853
IEDL.DBID BENPR
ISSN 1479-5876
IngestDate Fri Oct 04 13:15:33 EDT 2024
Sat Aug 17 00:40:45 EDT 2024
Thu Oct 10 17:14:41 EDT 2024
Fri Feb 23 00:21:42 EST 2024
Fri Feb 02 04:35:55 EST 2024
Thu Sep 12 18:07:10 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c415t-f4c66cef565245c33ef6e674f133600b3b002fb1cf1a4642f729ca7f415ff0853
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5133-1438
OpenAccessLink https://www.proquest.com/docview/2902138530?pq-origsite=%requestingapplication%
PQID 2902138530
PQPubID 43076
ParticipantIDs doaj_primary_oai_doaj_org_article_3bf8f3c0d28646be98cfaf26d9a0b507
proquest_miscellaneous_2892946166
proquest_journals_2902138530
gale_infotracmisc_A773875512
gale_infotracacademiconefile_A773875512
crossref_primary_10_1186_s12967_023_04718_y
PublicationCentury 2000
PublicationDate 2023-11-22
PublicationDateYYYYMMDD 2023-11-22
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-22
  day: 22
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal of translational medicine
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References SJ Conn (4718_CR88) 2015; 160
EP Carter (4718_CR7) 2015; 25
SB Zhang (4718_CR62) 2019; 10
DL Mitchell (4718_CR42) 2010; 316
EA Wellberg (4718_CR28) 2018; 3
N Javidi-Sharifi (4718_CR32) 2019; 8
S Sandhu (4718_CR1) 2021; 398
HG Vuong (4718_CR12) 2021; 155
Y Kong (4718_CR25) 2023; 83
E Labanca (4718_CR33) 2021; 5
M Armakola (4718_CR56) 2012; 44
W Liu (4718_CR19) 2019; 14
M Kanai (4718_CR38) 2009; 438
A Giacomini (4718_CR3) 2021; 101
O Bogatyrova (4718_CR27) 2021; 2021
D Orozco (4718_CR70) 2013; 91
LS Kristensen (4718_CR53) 2021; 19
X Wan (4718_CR84) 2014; 6
A Hopkins (4718_CR45) 2017; 15
KH Ho (4718_CR17) 2022; 113
AF Messmer-Blust (4718_CR39) 2012; 49
R Parakati (4718_CR41) 2013; 288
S Wang (4718_CR57) 2021; 12
JC Schwartz (4718_CR69) 2012; 26
CG Lucas (4718_CR13) 2020; 8
KQ Wang (4718_CR51) 2022; 51
M Musumeci (4718_CR16) 2011; 30
R Parakati (4718_CR43) 2002; 277
NO Tiryakioglu (4718_CR80) 2017; 77
L Errichelli (4718_CR87) 2017; 8
JU Guo (4718_CR22) 2014; 15
C Chu (4718_CR20) 2012; 61
W Wang (4718_CR79) 2020; 81
DL Mitchell (4718_CR40) 2010; 21
Y Chen (4718_CR64) 2019; 26
JR Brewer (4718_CR5) 2016; 30
TB Hansen (4718_CR75) 2013; 495
A Servetto (4718_CR34) 2021; 1876
TM Eidem (4718_CR59) 2016; 428
A Bronisz (4718_CR67) 2014; 289
M Seyed (4718_CR46) 2007; 400
Y Feng (4718_CR71) 2019; 10
S Terry (4718_CR82) 2015; 6
L Stoll (4718_CR63) 2020; 11
X Gao (4718_CR24) 2021; 23
S Chen (4718_CR6) 2019; 176
P Kaur (4718_CR9) 2022
Y Tang (4718_CR15) 2018; 37–52
Y Bao (4718_CR49) 2021; 13
Z Qu (4718_CR55) 2021; 12
J Zhong (4718_CR68) 2022; 530
CK Chen (4718_CR52) 2021; 81
FE Loughlin (4718_CR65) 2019; 59
V Mugoni (4718_CR86) 2022; 524
H Uranishi (4718_CR21) 2001; 276
PF Zhang (4718_CR50) 2019; 18
M McNicholas (4718_CR35) 2023; 13
T Lu (4718_CR37) 2018; 423
N Turner (4718_CR31) 2010; 10
HA Elmarakeby (4718_CR4) 2021; 598
C Thoma (4718_CR85) 2014; 11
H Li (4718_CR18) 2022; 37
A Masuda (4718_CR66) 2016; 7
A Panio (4718_CR81) 2022; 9
Z Su (4718_CR2) 2022; 114
F Saaoud (4718_CR76) 2021; 220
J Zhong (4718_CR26) 2023; 14
PJ O'Shea (4718_CR47) 2007; 148
G Stein-O'Brien (4718_CR14) 2018; 10
PR Pandey (4718_CR60) 2020; 48
M Katoh (4718_CR8) 2014; 34
R Parakati (4718_CR44) 2005; 280
B Mariz (4718_CR29) 2018; 47
L Chellini (4718_CR58) 2020; 39
M Katsu (4718_CR77) 2019; 708
R Roskoski Jr (4718_CR30) 2020; 151
JH Jeong (4718_CR74) 2017; 65
S Minisola (4718_CR11) 2017; 3
JL Carstens (4718_CR83) 2014; 74
G Di Timoteo (4718_CR89) 2020; 31
D Capece (4718_CR72) 2022; 43
TA Bale (4718_CR10) 2020; 8
M Seyed (4718_CR48) 2008; 44
S Orsten (4718_CR78) 2021; 95
T Helsten (4718_CR36) 2016; 22
Z Li (4718_CR54) 2015; 22
A Ivanov (4718_CR23) 2015; 10
VM Conn (4718_CR61) 2023; 41
AA Grosset (4718_CR73) 2019; 16
References_xml – volume: 438
  start-page: 49
  issue: 1–2
  year: 2009
  ident: 4718_CR38
  publication-title: Gene
  doi: 10.1016/j.gene.2009.03.004
  contributor:
    fullname: M Kanai
– volume: 7
  start-page: 330
  issue: 3
  year: 2016
  ident: 4718_CR66
  publication-title: Wiley Interdiscip Rev RNA
  doi: 10.1002/wrna.1338
  contributor:
    fullname: A Masuda
– volume: 3
  issue: 14
  year: 2018
  ident: 4718_CR28
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.120594
  contributor:
    fullname: EA Wellberg
– volume: 12
  start-page: 4908
  issue: 1
  year: 2021
  ident: 4718_CR57
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-25082-9
  contributor:
    fullname: S Wang
– volume: 11
  start-page: 5611
  issue: 1
  year: 2020
  ident: 4718_CR63
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-19381-w
  contributor:
    fullname: L Stoll
– volume: 151
  year: 2020
  ident: 4718_CR30
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2019.104567
  contributor:
    fullname: R Roskoski Jr
– volume: 30
  start-page: 751
  issue: 7
  year: 2016
  ident: 4718_CR5
  publication-title: Genes Dev
  doi: 10.1101/gad.277137.115
  contributor:
    fullname: JR Brewer
– volume: 113
  start-page: 540
  issue: 2
  year: 2022
  ident: 4718_CR17
  publication-title: Cancer Sci
  doi: 10.1111/cas.15240
  contributor:
    fullname: KH Ho
– volume: 14
  start-page: 4467
  issue: 1
  year: 2023
  ident: 4718_CR26
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-40212-1
  contributor:
    fullname: J Zhong
– volume: 8
  start-page: 21
  issue: 1
  year: 2020
  ident: 4718_CR10
  publication-title: Acta Neuropathol Commun
  doi: 10.1186/s40478-020-00898-6
  contributor:
    fullname: TA Bale
– volume: 148
  start-page: 5966
  issue: 12
  year: 2007
  ident: 4718_CR47
  publication-title: Endocrinology
  doi: 10.1210/en.2007-0114
  contributor:
    fullname: PJ O'Shea
– volume: 59
  start-page: 134
  year: 2019
  ident: 4718_CR65
  publication-title: Curr Opin Struct Biol
  doi: 10.1016/j.sbi.2019.07.012
  contributor:
    fullname: FE Loughlin
– volume: 26
  start-page: 2690
  issue: 24
  year: 2012
  ident: 4718_CR69
  publication-title: Genes Dev
  doi: 10.1101/gad.204602.112
  contributor:
    fullname: JC Schwartz
– volume: 21
  start-page: 2780
  issue: 15
  year: 2010
  ident: 4718_CR40
  publication-title: Mol Biol Cell
  doi: 10.1091/mbc.e10-04-0290
  contributor:
    fullname: DL Mitchell
– volume-title: Leukemia
  year: 2022
  ident: 4718_CR9
  contributor:
    fullname: P Kaur
– volume: 44
  start-page: 1302
  issue: 12
  year: 2012
  ident: 4718_CR56
  publication-title: Nat Genet
  doi: 10.1038/ng.2434
  contributor:
    fullname: M Armakola
– volume: 25
  start-page: 221
  issue: 4
  year: 2015
  ident: 4718_CR7
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2014.11.003
  contributor:
    fullname: EP Carter
– volume: 23
  start-page: 278
  issue: 3
  year: 2021
  ident: 4718_CR24
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-021-00639-4
  contributor:
    fullname: X Gao
– volume: 277
  start-page: 9278
  issue: 11
  year: 2002
  ident: 4718_CR43
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M108411200
  contributor:
    fullname: R Parakati
– volume: 22
  start-page: 256
  issue: 3
  year: 2015
  ident: 4718_CR54
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/nsmb.2959
  contributor:
    fullname: Z Li
– volume: 37
  start-page: 2832
  issue: 12
  year: 2022
  ident: 4718_CR18
  publication-title: Environ Toxicol
  doi: 10.1002/tox.23640
  contributor:
    fullname: H Li
– volume: 423
  start-page: 36
  year: 2018
  ident: 4718_CR37
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2018.02.015
  contributor:
    fullname: T Lu
– volume: 428
  start-page: 2652
  issue: 12
  year: 2016
  ident: 4718_CR59
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2016.02.019
  contributor:
    fullname: TM Eidem
– volume: 10
  start-page: 792
  issue: 11
  year: 2019
  ident: 4718_CR71
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-019-2028-9
  contributor:
    fullname: Y Feng
– volume: 43
  start-page: 757
  issue: 9
  year: 2022
  ident: 4718_CR72
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2022.07.004
  contributor:
    fullname: D Capece
– volume: 101
  start-page: 569
  issue: 2
  year: 2021
  ident: 4718_CR3
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00005.2020
  contributor:
    fullname: A Giacomini
– volume: 10
  start-page: 116
  issue: 2
  year: 2010
  ident: 4718_CR31
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2780
  contributor:
    fullname: N Turner
– volume: 524
  start-page: 57
  year: 2022
  ident: 4718_CR86
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2021.10.011
  contributor:
    fullname: V Mugoni
– volume: 15
  start-page: 1341
  issue: 10
  year: 2017
  ident: 4718_CR45
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-17-0185
  contributor:
    fullname: A Hopkins
– volume: 114
  start-page: 1378
  issue: 4
  year: 2022
  ident: 4718_CR2
  publication-title: Cancer Sci
  doi: 10.1111/cas.15694
  contributor:
    fullname: Z Su
– volume: 49
  start-page: 249
  issue: 3
  year: 2012
  ident: 4718_CR39
  publication-title: J Vasc Res
  doi: 10.1159/000335180
  contributor:
    fullname: AF Messmer-Blust
– volume: 34
  start-page: 280
  issue: 2
  year: 2014
  ident: 4718_CR8
  publication-title: Med Res Rev
  doi: 10.1002/med.21288
  contributor:
    fullname: M Katoh
– volume: 400
  start-page: 150
  issue: 1–2
  year: 2007
  ident: 4718_CR46
  publication-title: Gene
  doi: 10.1016/j.gene.2007.06.010
  contributor:
    fullname: M Seyed
– volume: 220
  year: 2021
  ident: 4718_CR76
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2020.107715
  contributor:
    fullname: F Saaoud
– volume: 155
  start-page: 225
  issue: 3
  year: 2021
  ident: 4718_CR12
  publication-title: J Neurooncol
  doi: 10.1007/s11060-021-03890-9
  contributor:
    fullname: HG Vuong
– volume: 10
  start-page: 170
  issue: 2
  year: 2015
  ident: 4718_CR23
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2014.12.019
  contributor:
    fullname: A Ivanov
– volume: 26
  start-page: 1346
  issue: 7
  year: 2019
  ident: 4718_CR64
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-018-0220-6
  contributor:
    fullname: Y Chen
– volume: 8
  start-page: 151
  issue: 1
  year: 2020
  ident: 4718_CR13
  publication-title: Acta Neuropathol Commun
  doi: 10.1186/s40478-020-01027-z
  contributor:
    fullname: CG Lucas
– volume: 1876
  issue: 2
  year: 2021
  ident: 4718_CR34
  publication-title: Biochim Biophys Acta Rev Cancer
  doi: 10.1016/j.bbcan.2021.188595
  contributor:
    fullname: A Servetto
– volume: 16
  issue: 7
  year: 2019
  ident: 4718_CR73
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1002847
  contributor:
    fullname: AA Grosset
– volume: 8
  start-page: 14741
  year: 2017
  ident: 4718_CR87
  publication-title: Nat Commun
  doi: 10.1038/ncomms14741
  contributor:
    fullname: L Errichelli
– volume: 598
  start-page: 348
  issue: 7880
  year: 2021
  ident: 4718_CR4
  publication-title: Nature
  doi: 10.1038/s41586-021-03922-4
  contributor:
    fullname: HA Elmarakeby
– volume: 44
  start-page: 510
  issue: 3
  year: 2008
  ident: 4718_CR48
  publication-title: J Mol Cell Cardiol
  doi: 10.1016/j.yjmcc.2007.12.008
  contributor:
    fullname: M Seyed
– volume: 83
  start-page: 3077
  issue: 18
  year: 2023
  ident: 4718_CR25
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-22-3997
  contributor:
    fullname: Y Kong
– volume: 47
  start-page: 816
  issue: 9
  year: 2018
  ident: 4718_CR29
  publication-title: J Oral Pathol Med
  doi: 10.1111/jop.12773
  contributor:
    fullname: B Mariz
– volume: 18
  start-page: 179
  issue: 1
  year: 2019
  ident: 4718_CR50
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1111-2
  contributor:
    fullname: PF Zhang
– volume: 160
  start-page: 1125
  issue: 6
  year: 2015
  ident: 4718_CR88
  publication-title: Cell
  doi: 10.1016/j.cell.2015.02.014
  contributor:
    fullname: SJ Conn
– volume: 12
  issue: 4
  year: 2021
  ident: 4718_CR55
  publication-title: mBio
  doi: 10.1128/mBio.01017-21
  contributor:
    fullname: Z Qu
– volume: 6
  issue: 252
  year: 2014
  ident: 4718_CR84
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.3009332
  contributor:
    fullname: X Wan
– volume: 8
  year: 2019
  ident: 4718_CR32
  publication-title: Elife
  doi: 10.7554/eLife.40033
  contributor:
    fullname: N Javidi-Sharifi
– volume: 77
  start-page: P6
  issue: 4
  year: 2017
  ident: 4718_CR80
  publication-title: Cancer Res.
  contributor:
    fullname: NO Tiryakioglu
– volume: 288
  start-page: 13876
  issue: 19
  year: 2013
  ident: 4718_CR41
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M113.457648
  contributor:
    fullname: R Parakati
– volume: 5
  start-page: 164
  issue: 2
  year: 2021
  ident: 4718_CR33
  publication-title: Eur Urol Oncol
  doi: 10.1016/j.euo.2021.10.001
  contributor:
    fullname: E Labanca
– volume: 398
  start-page: 1075
  issue: 10305
  year: 2021
  ident: 4718_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00950-8
  contributor:
    fullname: S Sandhu
– volume: 37–52
  start-page: 160
  issue: 1
  year: 2018
  ident: 4718_CR15
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-018-0813-4
  contributor:
    fullname: Y Tang
– volume: 276
  start-page: 13395
  issue: 16
  year: 2001
  ident: 4718_CR21
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M011176200
  contributor:
    fullname: H Uranishi
– volume: 2021
  start-page: 136
  issue: 151
  year: 2021
  ident: 4718_CR27
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2021.04.005
  contributor:
    fullname: O Bogatyrova
– volume: 13
  start-page: 228
  issue: 1
  year: 2021
  ident: 4718_CR49
  publication-title: Clin Epigenetics
  doi: 10.1186/s13148-021-01212-4
  contributor:
    fullname: Y Bao
– volume: 91
  start-page: 1343
  issue: 12
  year: 2013
  ident: 4718_CR70
  publication-title: J Mol Med (Berl)
  doi: 10.1007/s00109-013-1077-2
  contributor:
    fullname: D Orozco
– volume: 9
  year: 2022
  ident: 4718_CR81
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2022.861960
  contributor:
    fullname: A Panio
– volume: 74
  start-page: 609
  issue: 2
  year: 2014
  ident: 4718_CR83
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-1093
  contributor:
    fullname: JL Carstens
– volume: 61
  start-page: 3912
  year: 2012
  ident: 4718_CR20
  publication-title: J Vis Exp
  contributor:
    fullname: C Chu
– volume: 31
  issue: 6
  year: 2020
  ident: 4718_CR89
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2020.107641
  contributor:
    fullname: G Di Timoteo
– volume: 289
  start-page: 326
  issue: 1
  year: 2014
  ident: 4718_CR67
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M113.493874
  contributor:
    fullname: A Bronisz
– volume: 95
  start-page: 1
  year: 2021
  ident: 4718_CR78
  publication-title: J Helminthol
  doi: 10.1017/S0022149X2000098X
  contributor:
    fullname: S Orsten
– volume: 14
  start-page: 609
  year: 2019
  ident: 4718_CR19
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2019.01.003
  contributor:
    fullname: W Liu
– volume: 530
  start-page: 68
  year: 2022
  ident: 4718_CR68
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2022.01.016
  contributor:
    fullname: J Zhong
– volume: 81
  start-page: 18
  issue: 1
  year: 2020
  ident: 4718_CR79
  publication-title: Ann Endocrinol (Paris)
  doi: 10.1016/j.ando.2019.10.002
  contributor:
    fullname: W Wang
– volume: 10
  start-page: 4119
  issue: 1
  year: 2019
  ident: 4718_CR62
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-12049-0
  contributor:
    fullname: SB Zhang
– volume: 65
  start-page: 154
  issue: 1
  year: 2017
  ident: 4718_CR74
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2016.11.034
  contributor:
    fullname: JH Jeong
– volume: 13
  start-page: 1592
  issue: 7
  year: 2023
  ident: 4718_CR35
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-23-0004
  contributor:
    fullname: M McNicholas
– volume: 51
  start-page: 930
  issue: 8
  year: 2022
  ident: 4718_CR51
  publication-title: Pancreas
  doi: 10.1097/MPA.0000000000002119
  contributor:
    fullname: KQ Wang
– volume: 495
  start-page: 384
  issue: 7441
  year: 2013
  ident: 4718_CR75
  publication-title: Nature
  doi: 10.1038/nature11993
  contributor:
    fullname: TB Hansen
– volume: 48
  start-page: 3789
  issue: 7
  year: 2020
  ident: 4718_CR60
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa035
  contributor:
    fullname: PR Pandey
– volume: 81
  start-page: 4300
  issue: 20
  year: 2021
  ident: 4718_CR52
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2021.07.042
  contributor:
    fullname: CK Chen
– volume: 280
  start-page: 21284
  issue: 22
  year: 2005
  ident: 4718_CR44
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M410744200
  contributor:
    fullname: R Parakati
– volume: 3
  start-page: 17044
  year: 2017
  ident: 4718_CR11
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/nrdp.2017.44
  contributor:
    fullname: S Minisola
– volume: 30
  start-page: 4231
  issue: 41
  year: 2011
  ident: 4718_CR16
  publication-title: Oncogene
  doi: 10.1038/onc.2011.140
  contributor:
    fullname: M Musumeci
– volume: 176
  start-page: 831
  issue: 4
  year: 2019
  ident: 4718_CR6
  publication-title: Cell
  doi: 10.1016/j.cell.2019.01.025
  contributor:
    fullname: S Chen
– volume: 19
  start-page: 188
  issue: 3
  year: 2021
  ident: 4718_CR53
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00585-y
  contributor:
    fullname: LS Kristensen
– volume: 41
  start-page: 1309
  issue: 7
  year: 2023
  ident: 4718_CR61
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2023.05.002
  contributor:
    fullname: VM Conn
– volume: 708
  year: 2019
  ident: 4718_CR77
  publication-title: Neurosci Lett
  doi: 10.1016/j.neulet.2019.03.048
  contributor:
    fullname: M Katsu
– volume: 15
  start-page: 409
  issue: 7
  year: 2014
  ident: 4718_CR22
  publication-title: Genome Biol
  doi: 10.1186/s13059-014-0409-z
  contributor:
    fullname: JU Guo
– volume: 22
  start-page: 259
  issue: 1
  year: 2016
  ident: 4718_CR36
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-3212
  contributor:
    fullname: T Helsten
– volume: 10
  start-page: 37
  issue: 1
  year: 2018
  ident: 4718_CR14
  publication-title: Genome Med
  doi: 10.1186/s13073-018-0545-2
  contributor:
    fullname: G Stein-O'Brien
– volume: 6
  start-page: 11994
  issue: 14
  year: 2015
  ident: 4718_CR82
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2740
  contributor:
    fullname: S Terry
– volume: 39
  start-page: 51
  issue: 1
  year: 2020
  ident: 4718_CR58
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-020-01552-8
  contributor:
    fullname: L Chellini
– volume: 316
  start-page: 194
  issue: 2
  year: 2010
  ident: 4718_CR42
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2009.08.008
  contributor:
    fullname: DL Mitchell
– volume: 11
  start-page: 604
  issue: 11
  year: 2014
  ident: 4718_CR85
  publication-title: Nat Rev Urol
  doi: 10.1038/nrurol.2014.270
  contributor:
    fullname: C Thoma
SSID ssj0024549
Score 2.4429238
Snippet Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including...
Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2,...
Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including...
SourceID doaj
proquest
gale
crossref
SourceType Open Website
Aggregation Database
StartPage 1
SubjectTerms 1-Phosphatidylinositol 3-kinase
AKT protein
Analysis
Antibodies
Binding sites
Care and treatment
Cell migration
Chromatin
Chromosomes
circRNA
Circular RNA
Development and progression
Epigenetics
Extracellular signal-regulated kinase
FGFR1
Fibroblast growth factor receptor 1
Fibroblast growth factors
Fibroblasts
FUS
Gene amplification
Gene mutations
Gene rearrangement
Genetic aspects
Health aspects
Hybridization
Kinases
Medical prognosis
MicroRNA
miRNA
Mutation
NF-κB protein
P65
Point mutation
Post-transcription
Prostate cancer
Proteins
Signal transduction
Sperm
Survival analysis
Therapeutic targets
Transcription factors
Transcription regulation
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6ZO6SYMKgR6KWNuSZfu4DXVDIKFsu5CbsF6w0HqNH4H9W_2FnZHt0D2UXnoytiQsz4xmvsHzIOQCEEea6jJh0sYZE47XrJReM2NjnVhntQ553De38morru-yuz9afWFM2FQeeCLcimtfeG5imxZSSO3Kwvjap9KWdayzOY88yRZnaqmyB27PkiJTyFUPVg0UAtgnFqM2ZocjMxSq9f9NJwdDUz0jT2eESNfTzp6TR655QR7fzP_AX5Jfa9rs790Pumum_jXU7LoQTUo3t-twU32pNgkMp3RsWTd1m3c9DY-pPlDQct24w4BnOqCtWjQHvBbzHO7REe_pV5mtqu03WjeW9mM7RczCkp-7DRMStEbW0mFP2xDQ5_AaspOoQUHqaIj8mqp-vCLb6vP3yys2d15gBgz6wLwwUhrnAe0BKQ3nzksnc-HBowWEpDnadq8T45NagAfjAaKbOvew2HsAcfw1OWn2jXtDKDYzjkVd2DyTIva6FjEvrS6MtpjuZSPycWGEaqcCGyo4JoVUE9sUsE0FtqlDRD4hrx5mYnHs8ABERs0io_4lMhH5gJxWeISByqaeMxFgw1gMS63znIMbB1AoImdHM-HomePhRVbUfPR7lZYAmzjQII7I-4dhXInhbI3bjzCnAFQqZCLl2__xQafkSYqynSQsTc_IydCN7h1gpUGfh2PxG2ioEl8
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RAFB5qBfFFvGJslREEH2RskpmdTR5EVnEtwhZZXejbkLnJQk3SXIr7t_yFnjNJKgvVp5C5JGHO7TvkXAh5BYgjTXWeMGnjGROOFyyXXjNjY51YZ7UOedyrM3m6EV_OZ-cHZGp3NB5ge6Nrh_2kNs3F21-Xu_cg8O-CwGfypAWbBeIO1ofFqGvZ7ha5nQoukONXIvtbew-coSlx5sZ9e8Yp1PD_l6YO5md5n9wbcSNdDIR-QA5c-ZDcWY1_xh-R3wtaVlfugm7LoasNNdsmxJjS9dki3Cw_L9cJTKe0r1kz9KB3LQ3DVO8o6L6m32IYNO3Qgk36BF6L2Q9X6J639KucnSw332hRWtr29RBHC1t-btdMSNAls5p2Fa1DmJ_Da8hZogbZq6EhHmyoBfKYbJafvn88ZWM_BmbAzHfMCyOlcR4wIByl4dx56eRcePBzATdpjhbf68T4pBDg13gA7qaYe9jsPUA7_oQcllXpnhKKLY5jUWR2PpMi9roQMc-tzoy2mARmI_JmIoSqh7IbKrgrmVQD2RSQTQWyqV1EPiCtrldiyewwUDU_1CiBimufeW5im2ZSSO3yzPjCp9LmRawBFUfkNVJaIavBKZtizE-AD8YSWWoxn3Nw7gAgReR4byUIpNmfnnhFTfys0hzAFIcziCPy8noad2KQW-mqHtZkgFWFTKR89v9HHJG72PUeUyLT9Jgcdk3vngM26vSLwPB_AA_5DG8
  priority: 102
  providerName: Scholars Portal
Title A novel intronic circular RNA circFGFR1int2 up-regulates FGFR1 by recruiting transcriptional activators P65/FUS and suppressing miR-4687-5p to promote prostate cancer progression
URI https://www.proquest.com/docview/2902138530
https://search.proquest.com/docview/2892946166
https://doaj.org/article/3bf8f3c0d28646be98cfaf26d9a0b507
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZrC2MvZVfmtQsaDPYwRHxRZPtpJKNZGSSUbIGwF2HdSmCzPTsu5G_tF-4c2WnJw_biEEtygo90vu9I50LIe2AccazyiAkTThi3ScFy4RTTJlSRsUYpH8e9WIrrNf-6mWyGDbd2cKs86ESvqE2lcY98HOeARgmAS_ip_s2wahSerg4lNE7IWRxxPKY9m10tb1YP2fbA_DmEymRi3AK6gWIAnGIhamW2P4Ijn7X_X7rZA878KTkfmCKd9qJ9Rh7Z8jl5vBjOwl-QP1NaVnf2J92WfR0bqreN9yqlq-XUf5l_ma8iaI5pV7OmrzpvW-pvU7WnoO2abouOz3SHmHXQIPCzGO9whwZ5S2_EZDxff6NFaWjb1b3nLAz5tV0xLkB7TGq6q2jtHfssfvooJapxQjXUe4D12T9ekvX86vvnazZUYGAagH3HHNdCaOuA9cGr1ElinbAi5Q4sW2BKKkGMdyrSLio4WDIOqLouUgeDnQMyl7wip2VV2teEYlHjkBeZSSeCh04VPExyozKtDIZ9mYB8PAhC1n2iDekNlEzIXmwSxCa92OQ-IDOU1X1PTJLtb1TNrRzWnEyUy1yiQxNnggtl80y7wsXC5EWogAcH5ANKWuJShresiyEiAf4wJsWS0zRNwJwDShSQy6OesAT1cfNhrshBBbTyYcIG5N19M45Et7bSVh30yYCdchEJ8eb_j7ggT7DOPQZBxvElOd01nX0LbGinRuQk3aSjYeKP_J4CXBc8g-tq9uMvU0YODg
link.rule.ids 315,786,790,870,2115,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkYAL4qktLGAkJA7IahI7TnJCBVEKbCtUtlJvVvxClSAJSbtS_xa_kBkn3VUPcIoa20mVGX_zTTIPQl4D40gSXcRM2ihlwvGSFdJrZmykY-us1iGPe76Qs5X4sk7Xwwu3bgirPGBiAGpbG3xHPk4KsEYcjEv0rvnNsGsUfl0dWmjcJLcE5wL1PFtfO1wCnJ9Dokwuxx3YNoAFsFIsQkxm-yNjFGr2_wuZg7mZ3if3Bp5IJ71gH5AbrnpIbs-HL-GPyJ8JrepL95Nuqr6LDTWbNsSU0uViEn5MP02XMQwndNewtu857zoaTlO9p4B17W6DYc90ixbrgB9wW8x2uER3vKPfZDqerr7TsrK02zV93Cws-bVZMiEBO9KGbmvahLA-h8eQo0QNqlNLQ_xXX_vjMVlNP158mLGh_wIzYNa3zAsjpXEeOB88SsO589LJTHjwa4EnaY4W3uvY-LgU4Md4IOqmzDws9h6oHH9CTqq6cqeEYkvjSJS5zVIpIq9LEfHC6txoi0lfdkTeHgShmr7MhgruSS5VLzYFYlNBbGo_Iu9RVlczsUR2OFG3P9Sw4xTXPvfcRDbJpZDaFbnxpU-kLcpIAwsekTcoaYUbGZ6yKYd8BPjDWBJLTbKMgzMHhGhEzo5mwgY0x8MHXVEDAHTqWl1H5NXVMK7EoLbK1TuYkwM3FTKW8un_L_GS3JldzM_V-efF12fkLna8x3TIJDkjJ9t2554DL9rqF0H5_wJb0QvQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+intronic+circular+RNA+circFGFR1int2+up-regulates+FGFR1+by+recruiting+transcriptional+activators+P65%2FFUS+and+suppressing+miR-4687-5p+to+promote+prostate+cancer+progression&rft.jtitle=Journal+of+translational+medicine&rft.au=Wang%2C+Ruyue&rft.au=Zhong%2C+Jinjing&rft.au=Pan%2C+Xiuyi&rft.au=Su%2C+Zhengzheng&rft.date=2023-11-22&rft.pub=BioMed+Central&rft.eissn=1479-5876&rft.volume=21&rft.spage=1&rft_id=info:doi/10.1186%2Fs12967-023-04718-y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon